Abstract
Background Research on the link between cannabis use and the development of atherosclerotic cardiovascular disease (ASCVD) is inconsistent and challenging to interpret, given existing study limitations.
Aims To estimate the effects of genetically indexed cannabis use on the risk of coronary artery disease (CAD) and acute ischemic stroke (IS).
Methods 65 independent single-nucleotide polymorphisms (SNPs), obtained from a genome-wide association study on lifetime cannabis use (n=184,765), were employed as instruments to estimate the association between genetically indexed cannabis use and risk of CAD and IS using a two-sample Mendelian Randomization (MR) approach. Summary statistics on CAD (CARDIoGRAMplusC4D Consortium; 60,801 cases and 123,504 controls) and IS (MEGASTROKE; 34,217 cases and 406,111 controls) were obtained separately. A comprehensive review of the observational literature on cannabis use and CAD or IS was also performed and contrasted with MR results.
Results There was no causal effect of cannabis use on the risk of CAD (odds ratio (OR) per ever-users vs. never-users 0.93; 95% confidence interval (CI), 0.83 to 1.03) or IS (OR 1.05; 95%CI, 0.93 to 1.19). Sensitivity analyses yielded similar results, and no heterogeneity and directional pleiotropy were observed. Our meta-analysis of observational studies showed no significant association between ever use of cannabis with risk of CAD (k=6 studies; ORpooled=1.23, 95% CI 0.78 to 1.69), nor with IS (k=6 studies; ORpooled=1.22, 95% CI 0.95 to 1.50).
Conclusion Using a genetic approach approximating a clinical trial revealed no evidence for a causal effect of genetic predisposition to cannabis use on CAD or IS development. These findings are reassuring from a public health perspective, as ever cannabis use is unlikely to contribute to the risk of ASCVD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Summary statistics used in this study are publicly available for download at https://www.ru.nl/bsi/research/group-pages/substance-use-addiction-food-saf/vm-saf/genetics/international-cannabis-consortium-icc/ http://www.cardiogramplusc4d.org/data-downloads/ https://www.megastroke.org/ https://conservancy.umn.edu/handle/11299/2015 https://www.med.unc.edu/pgc/download-results/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study included summary statistics of different publicly available sources. First, a genetic study on cannabis use (from Pasman et al, in press Nature Neuroscience), which would like to acknowledge all participating groups of the International Cannabis Consortium, and in particular the members of the working group including Joelle Pasman, Karin Verweij, Nathan Gillespie, Eske Derks, and Jacqueline Vink. Pasman et al. Then, data on coronary artery disease and myocardial infarction have been contributed by CARDIoGRAMplusC4D investigators and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG. Data on stroke came from The MEGASTROKE project who received funding from sources specified at http://www.megastroke.org/acknowledgments.html. Then, a genetic study on smoking (from Liu et al, in press Nature Genetics) available at https://conservancy.umn.edu/handle/11299/2015. Finaly, some data from The Substance Use Disorders Working Group of the Psychiatric Genomics Consortium (PGC-SUD) which is supported by funds from NIDA and NIMH to MH109532 and gratefully acknowledge the participants in those studies without whom this effort would not be possible.
http://www.cardiogramplusc4d.org/data-downloads/
